Monoclonal antibody therapy

Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program

Retrieved on: 
Tuesday, March 30, 2021
Interleukin-6 receptor, Immune system, Medical specialties, Branches of biology, Interleukin 6, COVID-19, Monoclonal antibody therapy

This patient will be treated under an Individual Patient Expanded Access IND.

Key Points: 
  • This patient will be treated under an Individual Patient Expanded Access IND.
  • The treatment is planned to start in the second quarter of 2021, and will continue for six months.
  • Investigators at BWH will follow this patient with detailed routine safety, neurological, imaging and PET studies to evaluate microglial imaging.
  • The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

Retrieved on: 
Tuesday, March 30, 2021
Medical specialties, Monoclonal antibodies, Clinical medicine, Medicine, Interleukin-6 receptor, Foralumab, Anti-CD3 monoclonal antibody, Monoclonal antibody therapy, Clazakizumab

A recent clinical study in mild to moderate Covid-19 patients showed evidence that the nasally administered anti-CD3 monoclonal antibody reduced pulmonary and systemic inflammation and it was well tolerated.

Key Points: 
  • A recent clinical study in mild to moderate Covid-19 patients showed evidence that the nasally administered anti-CD3 monoclonal antibody reduced pulmonary and systemic inflammation and it was well tolerated.
  • Tiziana now plans a phase 2 randomized, placebo-controlled trial in Brazil for moderate to severe hospitalized Covid-19 patients to test the drug in a more compromised group of patients.
  • Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world.
  • The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

Totient Announces Formation of the New Scientific Advisory Board

Retrieved on: 
Wednesday, March 24, 2021
Immunology, Branches of biology, Monoclonal antibody therapy, Antibody, Biology, Life sciences

CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Totient , a human-derived therapeutic antibody discovery company based in Cambridge, MA, today announced the formation of its Scientific Advisory Board (SAB) including Prof. Simon Tavar, PhD, Bharath Ramsundar, PhD, Chris Powell, PhD, and Prof. Duncan Jodrell, DM.

Key Points: 
  • CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Totient , a human-derived therapeutic antibody discovery company based in Cambridge, MA, today announced the formation of its Scientific Advisory Board (SAB) including Prof. Simon Tavar, PhD, Bharath Ramsundar, PhD, Chris Powell, PhD, and Prof. Duncan Jodrell, DM.
  • Totient is enabling next generation cell therapies and other therapeutic modalities by building the largest library of human-derived antibodies to novel and known tissue-specific antigens.
  • The SAB will work closely with the Totient leadership team to help guide the further high throughput discovery and development efforts.
  • Previously, Dr. Powell was VP of Translational Medicine and Safety at GlaxoSmithKline and has notably served on Scientific Advisory Committees for the UK/EU Government and for the World Health Organization.

CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021

Retrieved on: 
Wednesday, March 24, 2021
Life sciences, Health sciences, Biotechnology, Immunology, Monoclonal antibody therapy, Biopharmaceutical

SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc.(Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody technology platform, today announced that it will host a virtual investor event at 1:00 p.m. 3:00 p.m.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc.(Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody technology platform, today announced that it will host a virtual investor event at 1:00 p.m. 3:00 p.m.
  • The event will focus on CytomXs Probody technology platform and the two conditionally activated ADCs, praluzatamab ravtansine (CX-2009) and CX-2029.
  • Probody therapeutics are conditionally activated antibodies designed to remain inactive until they are activated by proteases in the tumor microenvironment.
  • For additional information about CytomX Therapeutics, visit www.cytomx.com and follow us on LinkedIn and Twitter .

BITE Bispecific Antibody Drug Market Size Sales Clinical Trials Development Report 2025

Retrieved on: 
Thursday, March 11, 2021
Medical specialties, Immunology, Clinical medicine, Medicine, Bi-specific T-cell engager, Monoclonal antibody, Bispecific monoclonal antibody, Antibody, Blinatumomab, Emicizumab, Monoclonal antibody therapy

NEW DELHI, March 11, 2021 /PRNewswire/ -- "Global BiTE Antibodies Market, Price, Sales & Clinical Trials Insight 2025" Report Highlights:

Key Points: 
  • NEW DELHI, March 11, 2021 /PRNewswire/ -- "Global BiTE Antibodies Market, Price, Sales & Clinical Trials Insight 2025" Report Highlights:
    Currently Only 1 BiTE Commercially Available In Market: Blinatumomab (Blincyto)
    Blincyto Dosage & Market Sales Analysis ( Yearly, Quarterly & Regional Sales)
    Global BiTE Antibody Clinical Trials Indicators by Phase, Company, Country, Indication & Patient Segment
    "Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026" Report Highlights:
    Global Bispecific Antibody Market Opportunity: > US$ 10 Billion
    Global Bispecific Antibody Market Growth: 118% CAGR (2015 -2019)
    Global Bispecific Antibody Market Growth In 2019: 280% (> US$ 1.5 Billion)
    Hemlibra Sales & Market Share 2019: > US$ 1.4 Billion & > 80%
    The discovery of bispecific antibody drug market for specific diseases is the outcome of constant medical progression achieved in the pharmaceutical industry.
  • It is witnessed that the clinical applications in the cancer therapeutics industry got highly boosted by the emergence of BITE antibody drug market in terms of revenue and size.
  • The overall structural and healthcare clinical benefits associated with BITE specific antibody is also reported to deliver potential benefits to the cancer types that are hard-to-treat and solid.
  • As per the research conducted for Global BITE antibody drug market, it is observed that the market parameters will hold enormous potential as well as promising trends and opportunities with future research work.

BITE Bispecific Antibody Drug Market Size Sales Clinical Trials Development Report 2025

Retrieved on: 
Thursday, March 11, 2021
Medical specialties, Immunology, Clinical medicine, Medicine, Bi-specific T-cell engager, Monoclonal antibody, Bispecific monoclonal antibody, Antibody, Blinatumomab, Emicizumab, Monoclonal antibody therapy

NEW DELHI, March 11, 2021 /PRNewswire/ -- "Global BiTE Antibodies Market, Price, Sales & Clinical Trials Insight 2025" Report Highlights:

Key Points: 
  • NEW DELHI, March 11, 2021 /PRNewswire/ -- "Global BiTE Antibodies Market, Price, Sales & Clinical Trials Insight 2025" Report Highlights:
    Currently Only 1 BiTE Commercially Available In Market: Blinatumomab (Blincyto)
    Blincyto Dosage & Market Sales Analysis ( Yearly, Quarterly & Regional Sales)
    Global BiTE Antibody Clinical Trials Indicators by Phase, Company, Country, Indication & Patient Segment
    "Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026" Report Highlights:
    Global Bispecific Antibody Market Opportunity: > US$ 10 Billion
    Global Bispecific Antibody Market Growth: 118% CAGR (2015 -2019)
    Global Bispecific Antibody Market Growth In 2019: 280% (> US$ 1.5 Billion)
    Hemlibra Sales & Market Share 2019: > US$ 1.4 Billion & > 80%
    The discovery of bispecific antibody drug market for specific diseases is the outcome of constant medical progression achieved in the pharmaceutical industry.
  • It is witnessed that the clinical applications in the cancer therapeutics industry got highly boosted by the emergence of BITE antibody drug market in terms of revenue and size.
  • The overall structural and healthcare clinical benefits associated with BITE specific antibody is also reported to deliver potential benefits to the cancer types that are hard-to-treat and solid.
  • As per the research conducted for Global BITE antibody drug market, it is observed that the market parameters will hold enormous potential as well as promising trends and opportunities with future research work.

Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2021 Annual Meeting

Retrieved on: 
Wednesday, March 10, 2021
Branches of biology, Medical specialties, Immunology, Medicine, Tyrosine kinase receptors, Cancer treatments, Neurotrophic factors, HER2/neu, Monoclonal antibody therapy, Neuregulin 1, Antibody, ERBB3

All e-posters will be available on this website from Saturday, April 10 to Monday, June 21, 2021.

Key Points: 
  • All e-posters will be available on this website from Saturday, April 10 to Monday, June 21, 2021.
  • The posters will also be available on the Merus website as of Saturday, April 10, 2021.
  • In preclinical studies, Zeno also potently inhibits HER2/HER3 heterodimer formation and tumor growth in models harboring NRG1 fusions.
  • Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics .

Global $7.18 Billion Biosimilar Monoclonal Antibodies Markets, 2015-2019, 2023F, 2025F, 2030F

Retrieved on: 
Wednesday, March 10, 2021
Medical specialties, Life sciences, Clinical medicine, Immunology, Biotechnology, Biosimilar, Monoclonal antibody, Antibody, Adalimumab, Monoclonal antibody therapy

The biosimilar monoclonal antibodies market consists of sales of biosimilar monoclonal antibodies and related services by entities (organizations, sole traders and partnerships) that produce biosimilar monoclonal antibodies, which are used to treat patients with chronic diseases such as cancer, rheumatoid arthritis, and autoimmune disease.

Key Points: 
  • The biosimilar monoclonal antibodies market consists of sales of biosimilar monoclonal antibodies and related services by entities (organizations, sole traders and partnerships) that produce biosimilar monoclonal antibodies, which are used to treat patients with chronic diseases such as cancer, rheumatoid arthritis, and autoimmune disease.
  • Biosimilar monoclonal antibodies are highly similar to actual monoclonal antibodies in terms of pharmaceutical quality, safety, and efficacy, and are used to boost immunity by identifying and neutralizing foreign bodies.
  • Global Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
    4.2.
  • Global Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Global Biosimilar Monoclonal Antibodies Market Report 2020: Market is Expected to Recover in 2023 - Long-term Forecast to 2025 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 9, 2021
Biotechnology, Pharmaceutical, Health, Medical specialties, Life sciences, Clinical medicine, Biotechnology, Immunology, Biosimilar, Monoclonal antibody, Antibody, Adalimumab, Monoclonal antibody therapy

The "Biosimilar Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilar Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • The biosimilar monoclonal antibodies market consists of sales of biosimilar monoclonal antibodies and related services by entities (organizations, sole traders and partnerships) that produce biosimilar monoclonal antibodies, which are used to treat patients with chronic diseases such as cancer, rheumatoid arthritis, and autoimmune disease.
  • Global Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
    4.2.
  • Global Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference

Retrieved on: 
Monday, March 8, 2021
Immunology, Antibody, Branches of biology, Monoclonal antibody therapy, Biology

(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in a fireside chat at the 33rd Annual Roth Conference on Monday, March 15 at 2:00 p.m.

Key Points: 
  • (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in a fireside chat at the 33rd Annual Roth Conference on Monday, March 15 at 2:00 p.m.
  • An archived presentation will be available on the Merus website for a limited time.
  • Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics .
  • Investor and Media Inquiries: Jillian Connell Merus N.V. Investor Relations and Corporate Communications 617-955-4716 [email protected] Kathleen Farren Merus N.V. Communications Specialist 617-230-4165 [email protected]